Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more
Korea Bio-Gen Co.Ltd (318000) - Total Liabilities
Latest total liabilities as of September 2025: ₩4.38 Billion KRW
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has total liabilities worth ₩4.38 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Korea Bio-Gen Co.Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Korea Bio-Gen Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Korea Bio-Gen Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
Turkey | TL1.36 Billion |
|
Pro Inside Public Company Limited
BK:PIS
|
Thailand | ฿2.55 Billion |
|
Awaysis Capital Inc
PINK:AWCA
|
USA | $12.90 Million |
|
Eminent Gold Corp
OTCQB:EMGDF
|
USA | $225.01K |
|
SPECO Ltd
KQ:013810
|
Korea | ₩33.68 Billion |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
USA | $39.31 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Korea Bio-Gen Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Korea Bio-Gen Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Korea Bio-Gen Co.Ltd (2017–2024)
The table below shows the annual total liabilities of Korea Bio-Gen Co.Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩6.73 Billion | +72.56% |
| 2023-12-31 | ₩3.90 Billion | -52.04% |
| 2022-12-31 | ₩8.13 Billion | -21.76% |
| 2021-12-31 | ₩10.39 Billion | +257.63% |
| 2020-12-31 | ₩2.91 Billion | +17.54% |
| 2019-12-31 | ₩2.47 Billion | -72.00% |
| 2018-12-31 | ₩8.83 Billion | +12.08% |
| 2017-12-31 | ₩7.88 Billion | -- |